Skip to main content
Top
Published in: Tumor Biology 6/2013

01-12-2013 | Research Article

RETRACTED ARTICLE: Association between glutathione S-transferase M 1 null genotype and risk of ovarian cancer: a meta-analysis

Authors: Yihua Yin, Lingda Feng, Jing Sun

Published in: Tumor Biology | Issue 6/2013

Login to get access

Abstract

Though previous studies investigated the association between glutathione S-transferase M 1 (GSTM1) null genotype and ovarian cancer risk, the effect of GSTM1 null genotype on ovarian cancer risk was still unclear. To comprehensively quantify the association between GSTM1 null genotype and ovarian cancer risk, we performed a meta-analysis. Eleven studies from ten publications were identified from PubMed database. The pooled odds ratio (OR) with its 95 % confidence interval (CI) was used to assess the association. Meta-analysis of the total 11 studies showed that GSTM1 null genotype was not associated with ovarian cancer risk (OR = 1.03, 95 % CI 0.92–1.14, P = 0.625). The cumulative meta-analyses showed a trend of no association between GSTM1 null genotype and ovarian cancer risk as information accumulated by year. There was no evidence of publication bias in the meta-analysis. Meta-analysis of the 11 available studies shows that GSTM1 null genotype is not associated with ovarian cancer risk.
Literature
1.
go back to reference Gayther SA. Inherited risk of ovarian cancer and the implications for screening. Int J Gynecol Cancer. 2012;22 Suppl 1:S12–15.CrossRefPubMed Gayther SA. Inherited risk of ovarian cancer and the implications for screening. Int J Gynecol Cancer. 2012;22 Suppl 1:S12–15.CrossRefPubMed
2.
go back to reference Hall M, Gourley C, McNeish I, Ledermann J, Gore M, Jayson G, et al. Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer. 2013;108:250–8.CrossRefPubMedPubMedCentral Hall M, Gourley C, McNeish I, Ledermann J, Gore M, Jayson G, et al. Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer. 2013;108:250–8.CrossRefPubMedPubMedCentral
3.
go back to reference Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R. Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies. Lancet Oncol. 2012;13:946–56.CrossRefPubMed Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R. Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies. Lancet Oncol. 2012;13:946–56.CrossRefPubMed
4.
go back to reference Liliac L, Amalinei C, Balan R, Grigoras A, Caruntu ID. Ovarian cancer: insights into genetics and pathogeny. Histol Histopathol. 2012;27:707–19.PubMed Liliac L, Amalinei C, Balan R, Grigoras A, Caruntu ID. Ovarian cancer: insights into genetics and pathogeny. Histol Histopathol. 2012;27:707–19.PubMed
5.
go back to reference Ziebarth AJ, Landen Jr CN, Alvarez RD. Molecular/genetic therapies in ovarian cancer: Future opportunities and challenges. Clin Obstet Gynecol. 2012;55:156–72.CrossRefPubMed Ziebarth AJ, Landen Jr CN, Alvarez RD. Molecular/genetic therapies in ovarian cancer: Future opportunities and challenges. Clin Obstet Gynecol. 2012;55:156–72.CrossRefPubMed
6.
go back to reference Bolton KL, Ganda C, Berchuck A, Pharaoh PD, Gayther SA. Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the ovarian cancer association consortium (ocac). J Intern Med. 2012;271:366–78.CrossRefPubMed Bolton KL, Ganda C, Berchuck A, Pharaoh PD, Gayther SA. Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the ovarian cancer association consortium (ocac). J Intern Med. 2012;271:366–78.CrossRefPubMed
7.
go back to reference Lallas TA, McClain SK, Shahin MS, Buller RE. The glutathione S-transferase M1 genotype in ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2000;9:587–90.PubMed Lallas TA, McClain SK, Shahin MS, Buller RE. The glutathione S-transferase M1 genotype in ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2000;9:587–90.PubMed
8.
go back to reference Baxter SW, Thomas EJ, Campbell IG. GSTM1 null polymorphism and susceptibility to endometriosis and ovarian cancer. Carcinogenesis. 2001;22:63–5.CrossRefPubMed Baxter SW, Thomas EJ, Campbell IG. GSTM1 null polymorphism and susceptibility to endometriosis and ovarian cancer. Carcinogenesis. 2001;22:63–5.CrossRefPubMed
9.
go back to reference Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol. 2005;45:51–88.CrossRefPubMed Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol. 2005;45:51–88.CrossRefPubMed
10.
go back to reference Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology. 2000;61:154–66.CrossRefPubMed Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology. 2000;61:154–66.CrossRefPubMed
11.
go back to reference Sarhanis P, Redman C, Perrett C, Brannigan K, Clayton RN, Hand P, et al. Epithelial ovarian cancer: influence of polymorphism at the glutathione S-transferase GSTM1 and GSTT1 loci on P53 expression. Br J Cancer. 1996;74:1757–61.CrossRefPubMedPubMedCentral Sarhanis P, Redman C, Perrett C, Brannigan K, Clayton RN, Hand P, et al. Epithelial ovarian cancer: influence of polymorphism at the glutathione S-transferase GSTM1 and GSTT1 loci on P53 expression. Br J Cancer. 1996;74:1757–61.CrossRefPubMedPubMedCentral
12.
go back to reference Hengstler JG, Kett A, Arand M, Oesch-Bartlomowicz B, Oesch F, Pilch H, et al. Glutathione S-transferase T1 and M1 gene defects in ovarian carcinoma. Cancer Lett. 1998;130:43–8.CrossRefPubMed Hengstler JG, Kett A, Arand M, Oesch-Bartlomowicz B, Oesch F, Pilch H, et al. Glutathione S-transferase T1 and M1 gene defects in ovarian carcinoma. Cancer Lett. 1998;130:43–8.CrossRefPubMed
13.
go back to reference Goodman JE, Lavigne JA, Hengstler JG, Tanner B, Helzlsouer KJ, Yager JD. Catechol-o-methyltransferase polymorphism is not associated with ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2000;9:1373–6.PubMed Goodman JE, Lavigne JA, Hengstler JG, Tanner B, Helzlsouer KJ, Yager JD. Catechol-o-methyltransferase polymorphism is not associated with ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2000;9:1373–6.PubMed
14.
go back to reference Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G. Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype. Carcinogenesis. 2001;22:67–72.CrossRefPubMed Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G. Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype. Carcinogenesis. 2001;22:67–72.CrossRefPubMed
15.
go back to reference Morari EC, Lima AB, Bufalo NE, Leite JL, Granja F, Ward LS. Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients. J Cancer Res Clin Oncol. 2006;132:521–8.CrossRefPubMed Morari EC, Lima AB, Bufalo NE, Leite JL, Granja F, Ward LS. Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients. J Cancer Res Clin Oncol. 2006;132:521–8.CrossRefPubMed
16.
go back to reference Gates MA, Tworoger SS, Terry KL, Titus-Ernstoff L, Rosner B, De Vivo I, et al. Talc use, variants of the GSTM1, GSTT1, and NAT2 genes, and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:2436–44.CrossRefPubMedPubMedCentral Gates MA, Tworoger SS, Terry KL, Titus-Ernstoff L, Rosner B, De Vivo I, et al. Talc use, variants of the GSTM1, GSTT1, and NAT2 genes, and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:2436–44.CrossRefPubMedPubMedCentral
17.
go back to reference Khokhrin DV, Khrunin AV, Moiseev AA, Gorbunov VA. Limborskaia SA: [Association of polymorphisms in glutathione-S-transferase and DNA repair genes with ovarian cancer risk in the Russian population]. Genetika. 2012;48:901–4.PubMed Khokhrin DV, Khrunin AV, Moiseev AA, Gorbunov VA. Limborskaia SA: [Association of polymorphisms in glutathione-S-transferase and DNA repair genes with ovarian cancer risk in the Russian population]. Genetika. 2012;48:901–4.PubMed
18.
go back to reference Oliveira C, Lourenco GJ, Sagarra RA, Derchain SF, Segalla JG, Lima CS. Polymorphisms of glutathione S-transferase Mu 1 (GSTM1), Theta 1 (GSTT1), and Pi 1 (GSTP1) genes and epithelial ovarian cancer risk. Dis Markers. 2012;33:155–9.CrossRefPubMedPubMedCentral Oliveira C, Lourenco GJ, Sagarra RA, Derchain SF, Segalla JG, Lima CS. Polymorphisms of glutathione S-transferase Mu 1 (GSTM1), Theta 1 (GSTT1), and Pi 1 (GSTP1) genes and epithelial ovarian cancer risk. Dis Markers. 2012;33:155–9.CrossRefPubMedPubMedCentral
20.
21.
go back to reference Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
22.
go back to reference Muellerleile P, Mullen B. Sufficiency and stability of evidence for public health interventions using cumulative meta-analysis. Am J Public Health. 2006;96:515–22.CrossRefPubMedPubMedCentral Muellerleile P, Mullen B. Sufficiency and stability of evidence for public health interventions using cumulative meta-analysis. Am J Public Health. 2006;96:515–22.CrossRefPubMedPubMedCentral
24.
go back to reference Attia J, Thakkinstian A, D'Este C. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol. 2003;56:297–303.CrossRefPubMed Attia J, Thakkinstian A, D'Este C. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol. 2003;56:297–303.CrossRefPubMed
25.
go back to reference Wang B, Huang G, Wang D, Li A, Xu Z, Dong R, et al. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol. 2010;53:508–18.CrossRefPubMed Wang B, Huang G, Wang D, Li A, Xu Z, Dong R, et al. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol. 2010;53:508–18.CrossRefPubMed
26.
go back to reference Zhu Y, He Q, Wang J, Pan HF. The association between GSTM1 polymorphism and gastric cancer risk: a meta-analysis. Mol Biol Rep. 2012;39:685–91.CrossRefPubMed Zhu Y, He Q, Wang J, Pan HF. The association between GSTM1 polymorphism and gastric cancer risk: a meta-analysis. Mol Biol Rep. 2012;39:685–91.CrossRefPubMed
Metadata
Title
RETRACTED ARTICLE: Association between glutathione S-transferase M 1 null genotype and risk of ovarian cancer: a meta-analysis
Authors
Yihua Yin
Lingda Feng
Jing Sun
Publication date
01-12-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0995-5

Other articles of this Issue 6/2013

Tumor Biology 6/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine